New Drug Combinations Target Lyme Persister Cells

Researchers have identified novel drug combinations that may be effective against Lyme disease “persister” cells—forms of Borrelia burgdorferi that appear more tolerant to standard antibiotics in laboratory studies. :contentReference[oaicite:0]{index=0}

What Are Persister Forms?

Under stress—such as exposure to antibiotics or nutrient limitation—the Lyme bacterium can change shape.

Instead of the typical spiral form, it may convert into:

• Round body forms
• Microcolony aggregates

These forms appear to have lower metabolic activity and increased tolerance to certain antibiotics in in vitro studies.

“It is most likely that a single drug may not effectively kill all bacterial populations,” noted Feng.

Why Standard Antibiotics May Fall Short

Laboratory studies suggest that as Borrelia changes form, it may become less susceptible to commonly used antibiotics.

This has led researchers to explore whether combination therapies may be more effective than single-drug approaches.

Promising Drug Combinations

In laboratory testing, the combination of:

• Daptomycin
• Doxycycline
• Cefoperazone

was found to be highly active against resistant microcolony forms.

This combination achieved eradication of persister forms in vitro, without regrowth upon subculture.

Additional Drug Candidates

The study also identified multiple agents with activity against round body forms, including:

• Artemisinin
• Ciprofloxacin
• Fosfomycin
• Various sulfa-based drugs

These findings suggest that some existing medications may have activity beyond their current clinical use.

Important Limitations

These results are based on in vitro laboratory models.

It remains unclear:

• How often persister forms occur in human infection
• Which drug combinations are safe and effective in patients
• Whether these findings translate into improved clinical outcomes

Further studies, including clinical trials, are needed.

Clinical Perspective

This research highlights the complexity of Lyme disease and the possibility that different bacterial forms may respond differently to treatment.

While standard antibiotic regimens are effective for many patients, these findings may help explain why some individuals experience persistent symptoms.

Future treatment strategies may involve more targeted or combination approaches, though additional research is required.

Patients may benefit from understanding persistent symptoms, reviewing treatment variability, and considering coinfections when symptoms persist.

Key Takeaway

Laboratory studies suggest that combination therapies may be more effective than single antibiotics against certain forms of Borrelia burgdorferi—but clinical relevance remains under investigation.

References

1. Feng J et al. Front Microbiol. 2016.
2. Feng J et al. Antibiotics (Basel). 2015.
3. Feng J et al. PLoS One. 2015.
4. Miklossy J et al. J Neuroinflammation. 2008.
5. Lantos PM et al. Clin Infect Dis. 2014.

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention